COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know:

Guidance for cancer researchers:

Get the latest public health information from CDC:

Get the latest research information from NIH:

Simona Colantonio, Ph.D.

Director, CPTAC Antibody Characterization Laboratory, Frederick National Laboratory for Cancer Research

Simona Colantonio, Ph.D.

Dr. Colantonio is an expert in in mass spectrometry (MS) applied to biologically relevant molecules. In the early stages of her career, she worked at the Regina Elena National Cancer Institute of Rome, Italy and her studies focused on pharmacokinetics of anti-cancer drugs. Later, she moved to Maryland where she became involved in serum biomarker discovery while working as a guest researcher/post-doctoral fellow at SAIC-Frederick Inc. (now Leidos Biomedical Research). She has been collaborating with the ACL since 2009, when the lab was created. Since then, she has been able to achieve a deep knowledge of antibody/antigen interaction and she has become familiar with the growing number of antibody characterization tools available at the ACL. In 2018 she accepted a position as Visiting Professor at her Alma Mater, La Sapienza University of Rome, Italy (Pharmaceutical Chemistry and Technology Department, March 27th, 2018- April 26th, 2018). She has been serving as ACL Director since September 2019.

Dr. Colantonio has obtained the correspondent of a master’s degree in Pharmaceutical Chemistry and Technology and a Pharm. D. from la Sapienza University of Rome, Italy. From the same institution, she has received her Ph.D. in Pharmaceutical Sciences.